Allograft models enable characterisation of genomic drivers and treatment responses by modelling immune and micro-environmental changes more accurately than xenografts. Despite this, few models are available to the prostate cancer (PCa) community. This study presents a novel allograft model of high-risk, localised PCa. In characterising this model we have focused on its response to radiotherapy (RT).
Background
Prostate cancer (PCa) is the most common cancer in men and the fifth leading cause of cancer deaths 1 . It is estimated that 1.3 million new cases of PCa were diagnosed worldwide in 2018 alone 1 . The vast majority of PCa (91%) is localised disease at diagnosis 2 , and can be treated with a range of therapeutic modalities including surgery, androgen-deprivation therapy (ADT) and radiotherapy (RT).
Unfortunately, roughly 30% of high-risk localised PCa will develop into aggressive metastatic disease 3 , with limited treatment options. The current standard of care for these patients is ADT, but this has many adverse side effects and has a median relapse rate of only 11 months 4 .
As a result, efforts have focused on the use of RT to treat both localised and metastatic disease. RT delivers comparable patient outcomes to radical prostatectomy; survival and disease control, with less impact on patient quality of life 5 . However, one major challenge in further enhancing RT responses, by combining this modality with other treatments, is the paucity of appropriate preclinical PCa models in which to test these combinations.
The most commonly used immune-competent model is the TRAMP-C1 murine cell line, which can be allografted subcutaneously to generate more uniform, accessible prostate tumours 6 . The TRAMP-C1 model was generated by engineered expression of SV40 large T-antigen. Unfortunately, TRAMP-C1 allografts develop neuroendocrine tumours which are rare clinically, rather than adenocarcinomas which are most often seen in patients with localised prostate cancer (7) .
Consequently, novel PCa models that more accurately recapitulate human disease are urgently required. We developed an allograft model from the trp53 -/-/Pten -/transgenic mouse tumour; the 
Materials and Methods: Cell Line Derivation
Tissue fragments were centrifuged at 2000 rpm to remove extraneous blood and fat, PBS was removed, and remaining tissue digested in 1mg/ml collagenase/dispase in PBS for 30min at 37 o C.
Tissue fragments were further manually dissociated and the supernatant containing prostate cells collected. Collagnease/dispase was inactivated with EDTA at this time. The digestion process was repeated twice with remaining tissue fragments. Supernatant from the digestions was pooled and centrifuged at 2000 rpm and prostate cells were re-suspended in RPMI supplemented with 10% FBS, 1X pen/strep, 100nM DHT and rock inhibitor. These cells were then incubated for 10 minutes at 37 o C to allow for prostate fibroblasts to adhere to the tissue culture plastic. Remaining cell suspension, enriched for prostate epithelium was transferred to a new culture flask. This process of differential plating, allowing for initial adherence of fibroblasts and removal and retention of less adherent epithelial cells, was repeated for 10 passages, at which time the rock inhibitor was removed and the population remained homogenous.
Cell Line Generation and Maintenance
Mouse prostate epithelial cells (MPEC) were generated from dorsal, ventral and lateral lobes of the prostate from Probasin Cre -/-(Pb-Cre4) mice. Murine prostate cancer cells (DVL3) were generated from tumours derived from the dorsal, ventral and lateral prostate lobes of a trp53 -/-/Pten -/-Pb-Cre4 mouse 7 . Tissue was manually dissociated under sterile conditions and cell lines were generated as described in Cell Line Derivation and Supplementary Figure-1A .
The TRAMP-C1 murine prostate carcinoma cells were purchased from ATCC and maintained in DMEM high glucose medium, supplemented with 4mM L-Glutamine, 5% FBS, 5% Nu Serum, 0.005mg/ml of Bovine insulin, and 10nM Dehydroisoandrosterone (Sigma). The MPEC and DVL3 cell lines were maintained in RPMI-media supplemented with 10% FBS, L-Glutamine and 100nM DHT.
RNA Isolation and cDNA synthesis
Total RNA from cells was isolated using TriPure Isolation reagent (Roche) and phenol-chloroform extraction and cDNA synthesised using first strand cDNA (Roche) according to the respective manufacturer's instructions.
qRT-PCR
mRNA levels were determined by RT-PCR and measured on Roche LighCycler®480 II. All primers were obtained from Eurofins and sequences are detailed in ( Supplemental Table- experiment, cells were screened for mycoplasma contamination and MHV. Mice were housed on a 12/12 light/dark cycle and were given filtered water and fed ad libitum. Mice were inoculated subcutaneously with either 5x10 6 TRAMP-C1, 1x10 6 DVL3 cells or 1x10 6 mPEC cells.
Radiotherapy
Upon tumour establishment (4-6 weeks post inoculation), mice were randomised to treatment groups. Irradiation was performed when the tumours were between (~100mm 3 ). The tumour bearing mice were placed in a lead jig with an opening for the tumour and shielding for the rest of the body.
Radiotherapy was delivered using an AGO cell X-Ray unit and XSTRAHL in vivo irradiator at a dose rate of 2.086Gy/ minute. Tumour bearing mice received either single dose of 8Gy irradiation, or 5 fractions of 2Gy delivered over 5 consecutive days. Experimental groups contained at least 4-5 mice per group.
Sample Preparation
Tumour bearing mice were sacrificed at the indicated timepoints, tumours excised and fixed in 4% buffered formalin (Sigma Aldrich, UK) for 24 hours or collected in media for tumour disaggregation.
The formalin fixed tumour samples were transferred to 70% ethanol and processed to FFPE blocks.
Immunohistochemistry
Briefly, the slides were deparaffinised in xylene followed by rehydration in ethanol. Antigen retrieval was performed using pH 6 citrate buffer, followed by 3% H 2 0 2 block. Slides were incubated with 10% serum, prior to incubation with primary antibody overnight at 4° ( Supplementary Table- 2). Primary antibody was detected with either HRP detection kit or biotinylated secondary antibody followed by ABC detection kit (Vector Labs, USA). Slides were briefly incubated in DAB substrate (Vector Labs, USA), washed in water, and counter-stained using haematoxylin. For multiplex staining of mouse FFPE tumour sections, the opal TSA detection system (Opal 520®, 570® and 650®) were applied to sections following manufacturer's instruction and run on Leica BOND Rx automated system. The slides were counterstained with DAPI. Image analysis and quantification was performed using Definiens Tissue Phenomics Software.
Immunocytochemistry
Cells were seeded onto glass slides pre-coated with collagen type II (BD Biosciences) and left to adhere for 24 hours before fixation with 4% Paraformaldehyde at RT. Cells were permeabilised with 0.1% Triton X and blocked with 3% FBS-PBS. Primary antibody was added to slides and incubated for 1 hour at RT followed by incubation in secondary antibody for 1 hour at RT ( Supplemental Table- 
2).
Coverslips were mounted onto glass slides using Mounting media (Invitrogen) containing Dapi and imaged.
Flow cytometry on cell lines
Cells were incubated with primary antibody conjugated fluorophore for 30 minutes at 4 o C , washed with PBS and analysed on the Introducing the BD Accuri™ C6 Plus according to the manufacturer's instructions.
Flow cytometry on tumour tissue
To obtain single cell suspensions, tumours were processed using a gentleMacs dissociator and a murine dissociation kit (Miltenyi Biotec). For staining of cells, non-specific binding was blocked with rat anti-CD16/CD32 Fc block on ice. Cells were incubated with Gr-1 FITC, CD11b-APC (eBiosceince), washed in 1% FCS/PBS. For analysis, live cells were gated using vital dye exclusion (Invitrogen) and population phenotyped on FACs Canto (BD Bioscience) and analysed using Flow Jo software. An example of the gating strategy employed for selection of either CD45 -, CD45 + , or CD45 + CD11b + Gr1 + cells is provided in Supplementary Figure 2 .
RNA extraction for RNA seq analysis
RNA from FFPE mouse tumour tissue was extracted. Briefly, 2-4 (10uM) sections were transferred into RNAase free microcentrifuge tube. The paraffin was removed by incubating in xylene and ethanol. For lysate and total RNA purification, digestion buffer and proteinase-K was added to the samples as per manufacturer's instructions (Norgen kit). The samples were spun briefly followed by transferring the supernatant to a new RNAase free microcentrifuge tube. The RNA containing tubes were incubated for 15 minutes at 80 o C. The lysates were then passed through RNA purification microcolumn and centrifuged for 1 minute at 14,000 RPM. The microcolumns were washed according to manufacturer's instructions and the RNA eluted using the Elution solution (Norgen Kit).
RNA library preparation, sequencing and analysis
RNA libraries preparations were generated using the Quant-seq 3' mRNA-Seq FWD kit (Lexogen PART NO k15.96) according to manufacturer's instructions, with 500ng input RNA. FFPE-derived RNA was prepared using the suggested manufacturer's instructions. Libraries were pooled and sequenced on the NextSeq 500 using the FMHLS genomics CTU, yielding an average of 10M reads per sample. FASTQ files were aligned to the mm10 genomic reference using STAR aligner 8 and counts quantified at a gene level with HTseq-Counts 9 to yield 5-8M mapped reads per sample. Differential gene expression was performed between the irradiated and un-irradiated samples using the DESEQ 2. Differentially expressed genes were filtered; P-Value <0.05 and Log2 Fold-Change ≥1 (up-regulated) or ≤-1 (downregulated). Pathway analysis was performed on filtered genelists using the Reactome database 10 in Enrichr 11 , 12 . To identify enrichment of immune populations with the RT tumours vs untreated, enrichment analysis was performed using the open assess tool gene set enrichment analysis (GSEA) 13 , 14 with 1000 gene label permutations. Immune cells genes for macrophages, NK cells, T-cells and MDSC were taken from pervious published studies 15 -17 .
Results

Novel cell models express clinically relevant markers
Murine cell lines were generated via spontaneous immortalisation of normal prostate epithelium 
DVL3 engraftment in immunocompetent mice forms tumours, which accurately models human adenocarcinomas
To establish tumorigenic potential, mPEC, DVL3 and TRAMP-C1 cells were subcutaneously allografted into wild-type C57BL/6 mice, as all cell lines were originally generated from the C57BL/6 strain. Mice engrafted with mPEC cells did not develop any sign of disease after 12 weeks (data not shown), consistent with their status as untransformed but spontaneously immortalised wild-type prostate epithelial cells. DVL3 tumours grew at a similar rate to the TRAMP-C1 model ( Figure-2A) . Resultant tumours were characterised using a panel of relevant histological markers to determine their relevance as a model of human disease (Figure-2B) .
DVL3 tumours displayed heterogeneous pathology with neoplastic, glandular structures akin to human acinar adenocarcinoma (Supplemental Figure-3B ). Some regions of adenosarcoma were observed in the larger tumours as previously reported arising from trp53 -/-/Pten -/-Pb-Cre4 mice 7 . In contrast, TRAMP-C1 tumours were uniformly undifferentiated and lacked any trace of glandular morphology (Figure-2B) . Immunohistochemical staining revealed that the DVL3 tumours highly expressed CK8 throughout the entire tumour, particularly in the cells surrounding the lumen in the glandular structures (Figure-2B) . DVL3 tumours also had regions of CK5 positivity, with varied expression between the tumours. Conversely, in line with in vitro expression, TRAMP-C1 tumours lacked both CK8 and CK5. AR was present in the nucleus of cells throughout DVL3 tumours but was most apparent in clustered regions lining the lumen. TRAMP-C1 tumours had notably less AR staining and indeed some tumours lacked AR entirely (Figure-2B) . The clustered regions of AR positivity noted in the DVL3 tumours were not present in TRAMP-C1 tumours. To investigate if AR within the tumours was active, a downstream target of the AR; NKX3.1, was evaluated. NKX3.1 is a prostate-specific protein which is lost as PCa becomes castrate resistant 18 . Both the DVL3 and the TRAMP-C1 tumours were highly positive for NKX3.1 and expressed across the tumour section ( Supplementary Figure-3A) .
Vascularisation of the models was also investigated via CD34 immunostaining, which highlights endothelial cells, no notable differences were observed between the models (Supplemental Figure-3A ).
DVL3 tumours have immunosuppressive microenvironment similar to human prostate adenocarcinomas
To assess the tumour immune microenvironment, flow cytometric analysis was performed for T-cells (CD4+, CD8+), macrophages (F4/80), and MDSC, identified as dual Gr1+/CD11+ cells. The DVL3 tumours have a significantly higher proportion of Gr1+/CD11b+ cells compared to the TRAMP-C1 tumour (16.90% vs 6.61%, p=0.04, Figure-2C) . In contrast, both tumour lines have comparable level of macrophages (F4/80+) cells. The DVL3 tumours have significantly lower proportion of both cytotoxic CD8+ T-cells (0.187% vs. 2.05%) and CD4+ T-cells (0.36% vs. 4.31%) compared to the TRAMP-C1 tumours (p<0.005), similar to the immuno-suppressive microenvironment observed in PCa patients (11) . MDSCs drive immune-suppression and can confer resistance to radiotherapy 19 . Interestingly, the proportion of MDSCs in the DVL3 tumours is significantly higher compared to other syngeneic mouse models, such as CT26 (colorectal) and 4434 (melanoma) models, which are more sensitive to fractionated radiotherapy as demonstrated previously 20 (p<0.005, Figure-2D ).
Fractionated radiotherapy leads to marginal growth delay and alters the local tumour immune microenvironment
RT is a radical primary treatment administered to patients with high-risk localised PCa and also to patients with metastatic PCa. Therefore, therapeutic response to RT was evaluated in the DVL3 model. RT is known to induce immunogenic changes in tumour cells and can re-calibrate the immune contexture of the tumour microenvironment 22 . Therefore, further investigation via RNA-Seq was performed on DVL3 tumours treated with fractionated radiation and un-irradiated control tumours.
Interestingly, ENRICHR pathway analysis on differentially expressed genes highlighted a significant enrichment for pathways involved in interferon signalling (p<0.001) and STING activation (p<0.023) up-regulated in the fractionated tumours (Figure-3D) .
STING dependent cytosolic DNA sensing promotes type-1 interferon response and is critical for activation of innate immunity (19) . GSEA using gene sets for MDSCs and macrophages revealed significant up-regulation of the gene signatures; however; no increase was observed for genes associated with T-cells ( Figure-4 A-C) . In order to establish phenotypic significance of the activation of type-1 IFN-pathway, the expression of STING was evaluated via immunohistochemistry. Fractionated Figure-3C) . The increase in expression of STING on tumour cells correlated with a marginal increase in myeloid cell infiltrates (CD11b+) in the irradiated tumour (15.2% versus 23.3%, p=0.08). However, RT did not result in a significant increase in either CD8+ or CD4+ T-cells ( Figures-4B and C) . A marginal increase in NK cells (Nkp46) was observed which were predominantly localised around the necrotic areas in tumours (Figure-4B and C) . In addition, macrophage infiltration showed no increase as measured using (F4/80+) cells in the irradiated DVL3 tumours (Figure-4B and C) . Taken together with the GSEA, our results suggest that the activation of type-1 signalling in the irradiated DVL3 tumours could be due to influx of MDSCs and activation on innate immunity.
RT led to an abundant increase in STING expression, primarily from CK8+ tumour cells (Supplementary
Discussion
Whilst significant progress has been made in the treatment of metastatic, castrate-resistant prostate cancer (CRPC), the majority of these cancers are incurable. In order to have greater impact, it is important to understand how PCa evolves from localised disease so that more effective treatment combinations can be developed. The narrow range of pre-clinical models limits therapeutic development in prostate cancer. This study has developed two novel murine cell models; mPECs, which model normal prostate epithelium and may prove useful to engineer and test the impact of other clinically relevant driver mutations, and the tumorigenic DVL3 cell line. DVL3s were generated through deletion of genes that are frequently mutated in human PCa and are implicated in aggressive forms of the disease 7 ; thus, avoiding the introduction of tumorigenic viral proteins such as SV40 large T-antigen, which was used to generate the TRAMP-C1 cell line 6 . Although the TRAMP-C1 cell line has contributed significantly to PCa research, recent evidence indicates it generates neuroendocrine tumours, which clinically equates to only 0.5-2% of all PCa cases 23 . Conversely, the DVL3 develop tumours that represent an adenocarcinoma phenotype much more akin to most human PCa.
Transgenic models of PCa, and subsequent cell lines, generated from the trp53 -/-/Pten -/model form heterogeneous tumours (Figure-2B) (13) . Arguably, heterogeneity is one of the greatest benefits of this model, as most cell-based models are thought to be clonally selected due to genetic drift. As PCa is a multifocal heterogeneous disease the derivation of the bulk DVL3 population allows for research into PCa evolution in responses to treatment 24 . Tumours formed by the DVL3s maintained the heterogeneous CK8+/CK5+ glandular structures and regions of AR positivity, similar to the tumours from which they were derived. Additionally, unlike other trp53 -/-/Pten -/murine cell lines, previously described in the literature, the DVL3 can be allografted, presenting with immunological cold tumour immune microenvironment, mirroring observations seen clinically 7 , 25 .
Development of immune therapies as a method of harnessing the immune system's anti-tumour effects has recently gained traction 25 . Immune checkpoint inhibitors (ICI) have been used successfully to treat melanoma and bladder cancers; however, their impact on PCa is more limited 24 . Unlike melanoma and lung cancer, PCa has low levels of infiltrating CD8+ T cells 24 , 25 . The immune microenvironment of PCa has been implicated in a number of other ways including: host physiological factors, DNA damage response defects, low levels of tumour-associated antigens and the association of these factors with PTEN loss 24 . PTEN loss occurs in 20% of primary PCa patients and has been associated with poorer overall survival 7 , 24 . Additionally, melanoma patients with PTEN loss also show lower levels of tumour infiltrating lymphocytes (TIL) 24 . We have confirmed that this is also true in the DVL3 allografts, underscoring the more immuno-suppressed microenvironment of these tumours compared to the TRAMP-C1 tumours (Figure-2D) .
Comparing the DVL3 allografts to published transgenic models driven by Pten-deletion highlights other similarities and opportunities for future studies. For example Pten-deletion is known to lead to the expansion and immunosuppressive activities of Gr1 + /CD11b + myeloid derived suppressor cells (MDSC) 26 . High numbers of MDSCs in a Pten -/setting provide a protective effect on PCa cells from senescence, therefore sustaining tumour growth 26 , 27 . Mechanistically this has been observed to occur in CRPC patients and in transgenic prostate cancer models through the activation of the AR signalling due to paracrine IL-23 secretion by MDSCs 28 . Furthermore, influx of tumour MDSCs has been detected following RT, an observation which has been previously associated with the RT-induced up-regulation of STING expression in tumour cells 19 , 29 , 30 . Targeting MDSC, through IL-23 inhibition, in combination with RT and ADT could therefore provide a survival benefit for PCa patients. The DVL3 model recapitulates clinically relevant immune microenvironment features that have been previously observed in PCa transgenic models following RT, such as influx of MDSC (Figure-4) 19 , 26 , 28 . The DVL3 allograft model represents a significant improvement in prostate cancer research. DVL3 tumours more accurately recapitulate patient disease molecularly, histologically, and morphologically compared to alternative allograft models. Furthermore, they can be generated quickly and inexpensively compared to standard transgenic models, and tumours are readily accessible for therapeutic intervention. Importantly, DVL3 cells can be syngeneically engrafted into immune component hosts and respond to standard of care RT, with a similar immune influx. These data highlight the DVL3 cells as an improved PCa model, which may be used for the development and validation of novel therapeutics for prostate cancer, in particular immune-modulatory agents in combination with RT. C. 
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